drugset / Trial / NCT05427747

Meropenem vs Cefotaxime as Empirical Treatment of SBP

NCT05427747

Phase 4 Unknown 286 enrolled Assiut University
RandomizedParallel-groupDouble-blindTreatment

Summary

We aimed to evaluate whether meropenem is superior to cefotaxime for treatment of SBP empirically.

Timeline

Start
2023-01-01
Primary completion
2024-01
Completion
2024-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Cefotaxime Small molecule 2 g Intravenous
Subject Meropenem Small molecule 1 g Intravenous